{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:24:19Z","timestamp":1792790659678,"version":"4.5.0"},"reference-count":104,"publisher":"National Institute for Health and Care Research","issue":"34","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["15\/141\/09"],"award-info":[{"award-number":["15\/141\/09"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L022575\/1"],"award-info":[{"award-number":["MR\/L022575\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Cost-effectiveness analysis using quality-adjusted life-years as the measure of health benefit is commonly used to aid decision-makers. Clinical studies often do not include preference-based measures that allow the calculation of quality-adjusted life-years, or the data are insufficient. \u2018Mapping\u2019 can bridge this evidence gap; it entails estimating the relationship between outcomes measured in clinical studies and the required preference-based measures using a different data set. However, many methods for mapping yield biased results, distorting cost-effectiveness estimates.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n Develop existing and new methods for mapping; test their performance in case studies spanning different preference-based measures; and develop methods for mapping between preference-based measures.<\/jats:p>\n <\/jats:sec>\n \n Data sources<\/jats:title>\n \n Fifteen data sets for mapping from non-preference-based measures to preference-based measures for patients with head injury, breast cancer, asthma, heart disease, knee surgery and varicose veins were used. Four preference-based measures were covered: the EuroQoL-5 Dimensions, three-level version (\n n<\/jats:italic>\n \u2009=\u200911), EuroQoL-5 Dimensions, five-level version (\n n<\/jats:italic>\n \u2009=\u20092), Short Form questionnaire-6 Dimensions (\n n<\/jats:italic>\n \u2009=\u20091) and Health Utility Index Mark 3 (\n n<\/jats:italic>\n \u2009=\u20091). Sample sizes ranged from 852 to 136,327. For mapping between generic preference-based measures, data from FORWARD, the National Databank for Rheumatic Diseases (which includes the EuroQoL-5 Dimensions, three-level version, and EuroQoL-5 Dimensions, five-level version, in its 2011 wave), were used.\n <\/jats:p>\n <\/jats:sec>\n \n Main methods developed<\/jats:title>\n Mixture-model-based approaches for direct mapping, in which the dependent variable is the health utility value, including adaptations of methods developed to model the EuroQoL-5 Dimensions, three-level version, and beta regression mixtures, were developed, as were indirect methods, in which responses to the descriptive systems are modelled, for consistent multidirectional mapping between preference-based measures. A highly flexible approach was designed, using copulas to specify the bivariate distribution of each pair of EuroQoL-5 Dimensions, three-level version, and EuroQoL-5 Dimensions, five-level version, responses.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A range of criteria for assessing model performance is proposed. Theoretically, linear regression is inappropriate for mapping. Case studies confirm this. Flexible, direct mapping methods, based on different variants of mixture models with appropriate underlying distributions, perform very well for all preference-based measures. The precise form is important. Case studies show that a minimum of three components are required. Covariates representing disease severity are required as predictors of component membership. Beta-based mixtures perform similarly to the bespoke mixture approaches but necessitate detailed consideration of the number and location of probability masses. The flexible, bi-directional indirect approach performs well for testing differences between preference-based measures.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Case studies drew heavily on EuroQoL-5 Dimensions. Indirect methods could not be undertaken for several case studies because of a lack of coverage. These methods will often be unfeasible for preference-based measures with complex descriptive systems.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Mapping requires appropriate methods to yield reliable results. Evidence shows that widely used methods such as linear regression are inappropriate. More flexible methods developed specifically for mapping show that close-fitting results can be achieved. Approaches based on mixture models are appropriate for all preference-based measures. Some features are universally required (such as the minimum number of components) but others must be assessed on a case-by-case basis (such as the location and number of probability mass points).<\/jats:p>\n <\/jats:sec>\n \n Future research priorities<\/jats:title>\n Further research is recommended on (1) the use of the monotonicity concept, (2) the mismatch of trial and mapping distributions and measurement error and (3) the development of indirect methods drawing on methods developed for mapping between preference-based measures.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 24, No. 34. See the NIHR Journals Library website for further project information. This project was also funded by a Medical Research Council grant (MR\/L022575\/1).\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta24340","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T09:22:23Z","timestamp":1593595343000},"page":"1-68","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":37,"title":["Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods"],"prefix":"10.3310","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4474-5883","authenticated-orcid":true,"given":"M\u00f3nica","family":"Hern\u00e1ndez Alava","sequence":"first","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-1617","authenticated-orcid":true,"given":"Allan","family":"Wailoo","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5697-0976","authenticated-orcid":true,"given":"Stephen","family":"Pudney","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6365-7710","authenticated-orcid":true,"given":"Laura","family":"Gray","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8342-8421","authenticated-orcid":true,"given":"Andrea","family":"Manca","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2020,6]]},"reference":[{"key":"key20200720161205138_ref1-bib1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol \u2013 a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"key20200720161205138_ref1-bib2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based single index measure for health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Economics"},{"key":"key20200720161205138_ref1-bib3","volume-title":"SF-36 Health Survey Manual and Interpretation Guide","author":"Ware","year":"1993"},{"key":"key20200720161205138_ref1-bib4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-1-54","article-title":"The Health Utilities Index (HUI\u00ae): concepts, measurement properties, and applications","volume":"1","author":"Horseman","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"key20200720161205138_ref1-bib5","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"key20200720161205138_ref1-bib6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ"},{"issue":"Fall","key":"key20200720161205138_ref1-bib7","first-page":"14","article-title":"Revised SF-6D scoring programmes: a summary of improvements","volume":"40","author":"Brazier","year":"2008","journal-title":"Patient Reported Outcomes Newsletter"},{"key":"key20200720161205138_ref1-bib8","unstructured":"Furlong W, Feeny D, Torrance G, Goldsmith C, DePauw S, Zhu Z, et al. Multiplicative Multi-Attribute Utility Function for the Health Utilities Index Mark 3 (HUI3) System: A Technical Report. Hamilton, ON: McMaster University Centre for Health Economics and Policy Analysis (CHEPA); 1998. URL: www.chepa.org\/Files\/Working%20Papers\/WP%2098-11.pdf (accessed 30 October 2019)."},{"key":"key20200720161205138_ref1-bib9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/hec.787","article-title":"An empirical comparison of EQ-5D and SF-6D in liver transplant patients","volume":"12","author":"Longworth","year":"2003","journal-title":"Health Econ"},{"key":"key20200720161205138_ref1-bib10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/hec.789","article-title":"A view from the bridge: agreement between the SF-6D utility algorithm and the Health Utilities Index","volume":"12","author":"O\u2019Brien","year":"2003","journal-title":"Health Econ"},{"key":"key20200720161205138_ref1-bib11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hec.866","article-title":"A comparison of the EQ-5D and SF-6D across seven patient groups","volume":"13","author":"Brazier","year":"2004","journal-title":"Health Econ"},{"key":"key20200720161205138_ref1-bib12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2165\/00148365-200403020-00006","article-title":"Comparing utility scores before and after hearing-aid provision: results according to the EQ-5D, HUI3 and SF-6D","volume":"3","author":"Barton","year":"2004","journal-title":"Appl Health Econ Health Policy"},{"key":"key20200720161205138_ref1-bib13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1177\/0272989X13475716","article-title":"Common scale valuations across different preference-based measures: estimation using rank data","volume":"33","author":"Hern\u00e1ndez Alava","year":"2013","journal-title":"Med Decis Making"},{"key":"key20200720161205138_ref1-bib14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/0272989X15578127","article-title":"Mapping between 6 multiattribute utility instruments","volume":"36","author":"Chen","year":"2016","journal-title":"Med Decis Making"},{"key":"key20200720161205138_ref1-bib15","unstructured":"National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. Process and Methods [PMG9]. London: NICE; 2013. URL: www.nice.org.uk\/process\/pmg9\/chapter\/foreword (accessed 10 March 2018)."},{"key":"key20200720161205138_ref1-bib16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","article-title":"Spanish recommendations on economic evaluation of health technologies","volume":"11","author":"L\u00f3pez-Bastida","year":"2010","journal-title":"Eur J Health Econ"},{"key":"key20200720161205138_ref1-bib17","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Choices in Methods for Economic Evaluation. Saint-Denis: Haute Autorit\u00e9 de Sant\u00e9; 2012. URL: www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2012-10\/choices_in_methods_for_economic_evaluation.pdf (accessed 14 March 2018)."},{"key":"key20200720161205138_ref1-bib18","first-page":"S11","article-title":"Thai health technology assessment guideline development","volume":"91","author":"Teerawattananon","year":"2008","journal-title":"J Med Assoc Thail"},{"key":"key20200720161205138_ref1-bib19","unstructured":"Pharmaceutical Benefits Board. Preparing a Health Economic Evaluation to be Attached to the Application for Reimbursement Status and Wholesale Price for a Medicinal Product: Application Instructions. Helsinki: Ministry of Social Affairs and Health; 2017."},{"key":"key20200720161205138_ref1-bib20","unstructured":"Pharmaceutical Benefits Board. General Guidelines for Economic Evaluations from the Pharmaceutical Benefits Board. Stockholm: Dental and Pharmaceutical Benefits Board; 2017."},{"key":"key20200720161205138_ref1-bib21","unstructured":"Agency for Health Technology Assessment. Assessment. Guidelines for Conducting Health Technology Assessment (HTA). Warsaw: Agency for Health Technology Assessment; 2009."},{"key":"key20200720161205138_ref1-bib22","unstructured":"Pharmaceutical Management Agency (PHARMAC). Prescription for Pharmacoeconomic Analysis. Wellington: PHARMAC; 2015."},{"key":"key20200720161205138_ref1-bib23","unstructured":"CADTH. Guidelines for the Economic Evaluation of Health Technologies: Canada. Ottawa, ON: CADTH; 2017."},{"key":"key20200720161205138_ref1-bib24","volume-title":"Manual para la Elaboraci\u00f3n de Evaluaciones Econ\u00f3micas en Salud","author":"Moreno Viscaya","year":"2014"},{"key":"key20200720161205138_ref1-bib25","volume-title":"Guideline for the Conduct of Economic Evaluations in Health Care","author":"Nederland","year":"2016"},{"key":"key20200720161205138_ref1-bib26","volume-title":"Pharmacoeconomic Guidelines Around the World","author":"International Society for Pharmacoeconomics and Outcomes Research (ISPOR)"},{"key":"key20200720161205138_ref1-bib27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1477-7525-7-33","article-title":"Can we derive an \u2018exchange rate\u2019 between descriptive and preference-based outcome measures for stroke? Results from the transfer to utility (TTU) technique","volume":"7","author":"Mortimer","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"key20200720161205138_ref1-bib28","unstructured":"scharrheds.blogspot.com. Why Does My Mapping Not Predict Health Utilities at 1? Sheffield: School of Health and Related Research, University of Sheffield; 2019. URL: http:\/\/scharrheds.blogspot.com\/2019\/01\/why-does-my-mapping-not-predict-health.html (accessed 8 June 2020)."},{"key":"key20200720161205138_ref1-bib29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12955-018-0857-3","article-title":"Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement","volume":"16","author":"Dakin","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"key20200720161205138_ref1-bib30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40273-013-0069-y","article-title":"Good practice guidelines for the use of statistical regression models in economic evaluations","volume":"31","author":"Kearns","year":"2013","journal-title":"PharmacoEconomics"},{"key":"key20200720161205138_ref1-bib31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jval.2012.10.010","article-title":"Mapping to obtain EQ-5D utility values for use in NICE health technology assessments","volume":"16","author":"Longworth","year":"2013","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jval.2016.11.006","article-title":"Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR Good Practices for Outcomes Research Task Force Report","volume":"20","author":"Wailoo","year":"2017","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-015-0312-9","article-title":"The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration","volume":"33","author":"Petrou","year":"2015","journal-title":"PharmacoEconomics"},{"key":"key20200720161205138_ref1-bib34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/hec.941","article-title":"Parametric modelling of cost data: some simulation evidence","volume":"14","author":"Briggs","year":"2005","journal-title":"Health Econ"},{"key":"key20200720161205138_ref1-bib35","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/hec.1653","article-title":"Review of statistical methods for analysing healthcare resources and costs","volume":"20","author":"Mihaylova","year":"2011","journal-title":"Health Econ"},{"key":"key20200720161205138_ref1-bib36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40273-014-0153-y","article-title":"Mapping EQ-5D utility scores from the PedsQL\u2122 generic core scales","volume":"32","author":"Khan","year":"2014","journal-title":"PharmacoEconomics"},{"key":"key20200720161205138_ref1-bib37","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jval.2017.09.017","article-title":"Development of methods for the mapping of utilities using mixture models: mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in patients with asthma","volume":"21","author":"Gray","year":"2018","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/rheumatology\/36.5.551","article-title":"Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D)","volume":"36","author":"Hurst","year":"1997","journal-title":"Br J Rheumatol"},{"key":"key20200720161205138_ref1-bib39","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1214\/aos\/1176350366","article-title":"High breakdown-point and high efficiency robust estimates for regression","volume":"17","author":"Yohai","year":"1987","journal-title":"Ann Stat"},{"key":"key20200720161205138_ref1-bib40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40258-019-00467-6","article-title":"An updated systematic review of studies mapping (or cross-walking) measures of health-related quality of life to generic preference-based measures to generate utility values","volume":"17","author":"Mukuria","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"key":"key20200720161205138_ref1-bib41","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jval.2014.11.002","article-title":"Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results","volume":"17","author":"Pennington","year":"2014","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1524-4733.2010.00695.x","article-title":"Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?","volume":"13","author":"Pullenayegum","year":"2010","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2307\/1907382","article-title":"Estimation of relationships for limited dependent variables","volume":"26","author":"Tobin","year":"1958","journal-title":"Econometrica"},{"key":"key20200720161205138_ref1-bib44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jval.2018.05.008","article-title":"Cost-utility analysis using EQ-5D-5L data: does how the utilities are derived matter?","volume":"22","author":"Yang","year":"2019","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib45","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/0266476032000075985","article-title":"The use of finite mixture models to estimate the distribution of the Health Utilities Index in the presence of a ceiling effect","volume":"30","author":"Austin","year":"2003","journal-title":"J Applied Stat"},{"key":"key20200720161205138_ref1-bib46","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jval.2014.07.001","article-title":"Mapping between the Roland Morris Questionnaire and generic preference-based measures","volume":"17","author":"Khan","year":"2014","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib47","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1177\/0272989X15584921","article-title":"Mapping from the Parkinson\u2019s Disease Questionnaire PDQ-39 to the Generic EuroQol EQ-5D-3L: the value of mixture models","volume":"35","author":"Kent","year":"2015","journal-title":"Med Decis Making"},{"key":"key20200720161205138_ref1-bib48","doi-asserted-by":"publisher","DOI":"10.1177\/2381468317716440","article-title":"Mapping MOS-HIV to HUI3 and EQ-5D-3L in patients with HIV","volume":"2","author":"Joyce","year":"2017","journal-title":"MDM Policy Pract"},{"key":"key20200720161205138_ref1-bib49","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12955-016-0455-1","article-title":"Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients","volume":"14","author":"Khan","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"key20200720161205138_ref1-bib50","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jval.2011.12.014","article-title":"Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values","volume":"15","author":"Hern\u00e1ndez Alava","year":"2012","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib51","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1177\/0272989X13500720","article-title":"A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes","volume":"34","author":"Hern\u00e1ndez Alava","year":"2014","journal-title":"Med Decis Making"},{"key":"key20200720161205138_ref1-bib52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1477-7525-12-37","article-title":"Modelling the relationship between the WOMAC Osteoarthritis Index and EQ-5D","volume":"12","author":"Wailoo","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"key20200720161205138_ref1-bib53","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2015.02.016","article-title":"Modeling health state utility values in ankylosing spondylitis: comparisons of direct and indirect methods","volume":"18","author":"Wailoo","year":"2015","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jval.2016.09.2398","article-title":"Health state preference weights for the Glasgow Outcome Scale following traumatic brain injury: a systematic review and mapping study","volume":"20","author":"Ward Fuller","year":"2017","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/0272989X11416988","article-title":"Regression estimators for generic health-related quality of life and quality-adjusted life years","volume":"32","author":"Basu","year":"2012","journal-title":"Med Decis Making"},{"key":"key20200720161205138_ref1-bib56","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1177\/0272989X15587497","article-title":"Mapping functions in health-related quality of life: mapping from two cancer-specific health-related quality-of-life instruments to EQ-5D-3L","volume":"35","author":"Young","year":"2015","journal-title":"Med Decis Making"},{"key":"key20200720161205138_ref1-bib57","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40273-016-0446-4","article-title":"Mapping between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and five Multi-Attribute Utility Instruments (MAUIs)","volume":"35","author":"Kaambwa","year":"2017","journal-title":"PharmacoEconomics"},{"key":"key20200720161205138_ref1-bib58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12955-014-0163-7","article-title":"A non-linear beta-binomial regression model for mapping EORTC QLQ-C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches","volume":"12","author":"Khan","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"key20200720161205138_ref1-bib59","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1037\/1082-989X.11.1.54","article-title":"A better lemon squeezer? Maximum-likelihood regression with beta-distributed dependent variables","volume":"11","author":"Smithson","year":"2006","journal-title":"Psychol Methods"},{"key":"key20200720161205138_ref1-bib60","volume-title":"Deriving Preference-Based Single Indices From Non-Preference-Based Condition-Specific Instruments: Converting AQLQ into EQ5D Indices","author":"Tsuchiya","year":"2002"},{"key":"key20200720161205138_ref1-bib61","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0272989X05284108","article-title":"Estimating the association between SF-12 responses and EQ-5D utility values by response mapping","volume":"26","author":"Gray","year":"2006","journal-title":"Med Decis Making"},{"key":"key20200720161205138_ref1-bib62","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/rheumatology\/kes400","article-title":"The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis","volume":"52","author":"Hern\u00e1ndez Alava","year":"2013","journal-title":"Rheumatology"},{"key":"key20200720161205138_ref1-bib63","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/rssa.12072","article-title":"Prediction of patient-reported outcome measures via multivariate ordered probit models?","volume":"178","author":"Conigliani","year":"2015","journal-title":"J R Stat Soc Ser A"},{"key":"key20200720161205138_ref1-bib64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1536867X1801800105","article-title":"BETAMIX: a command for fitting mixture regression models for bounded dependent variables using the beta distribution","volume":"18","author":"Gray","year":"2018","journal-title":"Stata J"},{"key":"key20200720161205138_ref1-bib65","doi-asserted-by":"crossref","DOI":"10.1002\/0471721182","volume-title":"Finite Mixture Models","author":"McLachlan","year":"2000"},{"key":"key20200720161205138_ref1-bib66","first-page":"764","article-title":"Contribution to the discussion of paper by S. Richardson and P. J. Green","volume":"59","author":"Aitkin","year":"1997","journal-title":"J R Stat Soc Ser B"},{"key":"key20200720161205138_ref1-bib67","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/1536867X1501500307","article-title":"Fitting adjusted limited dependent variable mixture models to EQ-5D","volume":"15","author":"Hern\u00e1ndez Alava","year":"2015","journal-title":"Stata J"},{"key":"key20200720161205138_ref1-bib68","volume-title":"Valuing Health-related Quality of Life: An EQ-5D-5L Value Set for England","author":"Devlin","year":"2016"},{"key":"key20200720161205138_ref1-bib69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1561\/0800000005","article-title":"Copula modeling: an introduction for practitioners","volume":"1","author":"Zimmer","year":"2006","journal-title":"Foundations and Trends\u00ae in Econometrics"},{"key":"key20200720161205138_ref1-bib70","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jhealeco.2017.06.013","article-title":"Econometric modelling of multiple self-reports of health states: the switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis","volume":"55","author":"Hern\u00e1ndez-Alava","year":"2017","journal-title":"J Health Econ"},{"key":"key20200720161205138_ref1-bib71","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/1536867X1801800207","article-title":"Eq5Dmap: a command for mapping between EQ-5D-3L and EQ-5D-5L","volume":"18","author":"Hern\u00e1ndez-Alava","year":"2018","journal-title":"Stata J"},{"key":"key20200720161205138_ref1-bib72","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1536867X1601600114","article-title":"BICOP: a command for estimating bivariate ordinal regressions with residual dependence characterized by a copula function and normal mixture marginal?","volume":"16","author":"Hern\u00e1ndez-Alava","year":"2016","journal-title":"Stata J"},{"key":"key20200720161205138_ref1-bib73","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/0272989X09349961","article-title":"Mapping the modified Rankin Scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome","volume":"30","author":"Rivero-Arias","year":"2010","journal-title":"Med Decis Making"},{"key":"key20200720161205138_ref1-bib74","volume-title":"NICE DSU Technical Support Document 10: The Use of Mapping Methods to Estimate Health State Utility Values","author":"Longworth","year":"2011"},{"key":"key20200720161205138_ref1-bib75","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jval.2013.12.002","article-title":"Should linking replace regression when mapping from profile-based measures to preference-based measures?","volume":"17","author":"Fayers","year":"2014","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib76","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10198-009-0168-z","article-title":"A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures","volume":"11","author":"Brazier","year":"2010","journal-title":"Eur J Health Econ"},{"key":"key20200720161205138_ref1-bib77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bmb\/ldr049","article-title":"Mapping for economic evaluation","volume":"101","author":"Chuang","year":"2012","journal-title":"Br Med Bull"},{"key":"key20200720161205138_ref1-bib78","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/rheumatology\/keq155","article-title":"The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank","volume":"50","author":"Wolfe","year":"2011","journal-title":"Rheumatology"},{"key":"key20200720161205138_ref1-bib79","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"key20200720161205138_ref1-bib80","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/hec.1148","article-title":"A taxonomy of model structures for economic evaluation of health technologies","volume":"15","author":"Brennan","year":"2006","journal-title":"Health Econ"},{"key":"key20200720161205138_ref1-bib81","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1445-1433.2004.03029.x","article-title":"Developing Australia\u2019s first statewide trauma registry: what are the lessons?","volume":"74","author":"Cameron","year":"2004","journal-title":"ANZ J Surg"},{"key":"key20200720161205138_ref1-bib82","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","article-title":"Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument","volume":"15","author":"Brady","year":"1997","journal-title":"J Clin Oncol"},{"key":"key20200720161205138_ref1-bib83","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1093\/annonc\/mdw316","article-title":"Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent\/metastatic breast cancer","volume":"27","author":"Vrdoljak","year":"2016","journal-title":"Ann Oncol"},{"key":"key20200720161205138_ref1-bib84","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jval.2018.06.006","article-title":"Mapping the FACT-B instrument to EQ-5D-3L in patients with breast cancer using adjusted limited dependent variable mixture models versus response mapping","volume":"21","author":"Gray","year":"2018","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib85","volume-title":"Cross-National Comparison of Twelve Quality of Life Instruments. MIC Paper 1: Background, Questions, Instruments","author":"Richardson","year":"2012"},{"key":"key20200720161205138_ref1-bib86","unstructured":"European Medicines Agency (EMA). Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Asthma. London: EMA; 2015. URL: www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-asthma_en.pdf (accessed 30 October 2019)."},{"key":"key20200720161205138_ref1-bib87","first-page":"427","article-title":"Validation of the Asthma Quality of Life Questionnaire with momentary assessments of symptoms and functional limitations in patient daily life","volume":"55","author":"Everhart","year":"2010","journal-title":"Respir Care"},{"key":"key20200720161205138_ref1-bib88","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20200720161205138_ref1-bib89","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"82","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"key20200720161205138_ref1-bib90","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/S0959-8049(00)00186-6","article-title":"A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H & N35) in head and neck patients. EORTC Quality of Life Group","volume":"36","author":"Bjordal","year":"2000","journal-title":"Eur J Cancer"},{"key":"key20200720161205138_ref1-bib91","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"key20200720161205138_ref1-bib92","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1302\/0301-620x.80b1.7859","article-title":"Questionnaire on the perceptions of patients about total knee replacement","volume":"80","author":"Dawson","year":"1998","journal-title":"J Bone Joint Surg Br"},{"key":"key20200720161205138_ref1-bib93","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1302\/0301-620X.78B2.0780185","article-title":"Questionnaire on the perceptions of patients about total hip replacement","volume":"78","author":"Dawson","year":"1996","journal-title":"J Bone Joint Surg Br"},{"key":"key20200720161205138_ref1-bib94","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/qshc.2.1.5","article-title":"Measurement with varicose veins","volume":"2","author":"Garratt","year":"1993","journal-title":"Qual Heal Care"},{"key":"key20200720161205138_ref1-bib95","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ejvs.2012.11.016","article-title":"An online patient completed Aberdeen Varicose Vein Questionnaire can help to guide primary care referrals","volume":"45","author":"Ward","year":"2013","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"key20200720161205138_ref1-bib96","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/rheumatology\/keu039","article-title":"Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis","volume":"53","author":"Wailoo","year":"2014","journal-title":"Rheumatology"},{"key":"key20200720161205138_ref1-bib97","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jval.2017.09.004","article-title":"EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom","volume":"21","author":"Her\u00e1andez Alava","year":"2018","journal-title":"Value Health"},{"issue":"5","key":"key20200720161205138_ref1-bib98","doi-asserted-by":"publisher","DOI":"10.3310\/hta16050","article-title":"What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review","volume":"16","author":"Ara","year":"2012","journal-title":"Health Technol Assess"},{"key":"key20200720161205138_ref1-bib99","volume-title":"Questions and Answers in Attitude Surveys","author":"Schuman","year":"1996"},{"key":"key20200720161205138_ref1-bib100","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib101","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/ard.2007.076299","article-title":"Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis","volume":"67","author":"Choy","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20200720161205138_ref1-bib102","first-page":"3653","article-title":"Calibration","volume-title":"Handbook of Econometrics","author":"Dawkins","year":"2005"},{"key":"key20200720161205138_ref1-bib103","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jval.2012.07.003","article-title":"Mapping from disease-specific to generic health-related quality-of-life scales: a common factor model","volume":"16","author":"Lu","year":"2013","journal-title":"Value Health"},{"key":"key20200720161205138_ref1-bib104","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s41669-017-0027-2","article-title":"Statistical alchemy: conceptual validity and mapping to generate health state utility values","volume":"1","author":"Round","year":"2017","journal-title":"Pharmacoecon Open"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2033059","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta24340\/hta24340.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2033059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T20:26:42Z","timestamp":1723148802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta24340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":104,"journal-issue":{"issue":"34","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["10.3310\/hta24340"],"URL":"https:\/\/doi.org\/10.3310\/hta24340","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"9-2014","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"5-2019","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"11-2019","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}